EGFR and colorectal carcinoma: In our analysis, the subgroup of patients with chemorefractory CRC and increased ALK gene copy number had ha significantly lower likelihood to respond to anti-EGFR treatment, despite a RAS-RAF-PI3KCA wild-type status.